1,2-Dichloroethane → 1,1-dimethylethyl (2S)-4-[(5'-{[({2-chloro-5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)sulfonyl]-4-fluorophenyl}carbonyl)amino]methyl}-2'-fluoro-3-biphenylyl)methyl]-2-methyl-1-piperazinecarboxylate

HRID 564647ノート

反応式

HRID 564647 の反応式
[Cl:1][C:2]1[CH:10]=[C:9]([F:11])[C:8]([S:12]([NH:15][CH2:16][C:17]2[C:18]([NH:30][CH:31]3[CH2:36][CH2:35][O:34][CH2:33][CH2:32]3)=[C:19]3[CH:27]=[N:26][N:25]([CH2:28][CH3:29])[C:20]3=[N:21][C:22]=2[CH2:23][CH3:24])(=[O:14])=[O:13])=[CH:7][C:3]=1[C:4](O)=[O:5].[NH2:37][CH2:38][C:39]1[CH:40]=[CH:41][C:42]([F:66])=[C:43]([C:45]2[CH:50]=[CH:49][CH:48]=[C:47]([CH2:51][N:52]3[CH2:57][CH2:56][N:55]([C:58]([O:60][C:61]([CH3:64])([CH3:63])[CH3:62])=[O:59])[C@@H:54]([CH3:65])[CH2:53]3)[CH:46]=2)[CH:44]=1.C1C=CC2N(O)N=NC=2C=1.C(Cl)CCl>C(Cl)Cl>[Cl:1][C:2]1[CH:10]=[C:9]([F:11])[C:8]([S:12]([NH:15][CH2:16][C:17]2[C:18]([NH:30][CH:31]3[CH2:32][CH2:33][O:34][CH2:35][CH2:36]3)=[C:19]3[CH:27]=[N:26][N:25]([CH2:28][CH3:29])[C:20]3=[N:21][C:22]=2[CH2:23][CH3:24])(=[O:13])=[O:14])=[CH:7][C:3]=1[C:4]([NH:37][CH2:38][C:39]1[CH:40]=[CH:41][C:42]([F:66])=[C:43]([C:45]2[CH:50]=[CH:49][CH:48]=[C:47]([CH2:51][N:52]3[CH2:57][CH2:56][N:55]([C:58]([O:60][C:61]([CH3:62])([CH3:64])[CH3:63])=[O:59])[C@@H:54]([CH3:65])[CH2:53]3)[CH:46]=2)[CH:44]=1)=[O:5]

参加物

6

反応物 4

HCID 111,2-DichloroethaneHCID 757711-HydroxybenzotriazoleHCID 251325161,1-dimethylethyl (2S)-4-{[5'-(aminomethyl)-2'-fluoro-3-biphenylyl]methyl}-2-methyl-1-piperazinecarboxylateHCID 578132602-chloro-5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)sulfonyl]-4-fluorobenzoic acid

生成物 1

HCID 866332011,1-dimethylethyl (2S)-4-[(5'-{[({2-chloro-5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)sulfonyl]-4-fluorophenyl}carbonyl)amino]methyl}-2'-fluoro-3-biphenylyl)methyl]-2-methyl-1-piperazinecarboxylate

試薬・触媒・溶媒 1

HCID 6344Dichloromethane溶媒

実験手順

345(b) The 2-chloro-5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)sulfonyl]-4-fluorobenzoic acid, was dissolved in 3 mL of DCM with 1,1-dimethylethyl (2S)-4-{[5′-(aminomethyl)-2′-fluoro-3-biphenylyl]methyl}-2-methyl-1-piperazinecarboxylate (41.3 mg, 0.1 mmol), and then added in HOBt (1.0 eq, 14.0 mg), and EDC (1.0 eq, 19.0 mg). The resultant solution was stirred overnight. The solution was then purified using a Gilson to give 1,1-dimethylethyl (2S)-4-[(5′-{[({2-chloro-5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)sulfonyl]-4-fluorophenyl}carbonyl)amino]methyl}-2′-fluoro-3-biphenylyl)methyl]-2-methyl-1-piperazinecarboxylate.

後処理

  1. customThe solution was then purified

出典と根拠

ORDレコード
ord-f09bc4039ca94aa99d81e81ba9be0523
出典データセット
uspto-grants-2011_11
特許番号
US08067408B2

反応ノート

読み込み中…